Treating Endothelial Disease With One Cornea Donor
Edward Holland, MD, chief medical advisor, discussed an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.
Using CAR T Therapy in R/R Multiple Myeloma
Nina Shah, MD, and other experts discuss the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.
Selecting AAV Manufacturing Platforms
The chief scientific officer and chief medical officer of Ultragenyx Gene Therapy discussed the company’s future research in gene therapies.
Developing Oncolytic Cell Therapies With VISION
Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed the VISION platform the company uses to develop therapies.
Future Research in Gene and Cell Therapy Conditioning
Kevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.
Immunotherapy and CAR T-Cell Therapy: Stephen M. Ansell, MD, PhD
The chair of the Lymphoma Group at Mayo Clinic discussed incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.
Challenges With CAR T Therapy in Follicular Lymphoma: Sattva S. Neelapu, MD
The professor from the University of Texas Anderson Cancer Center discussed challenges surrounding CAR T-cell therapy for the treatment of follicular lymphoma and other lymphomas.
Future Research With CAR T in Lymphoma: Julie Vose, MD
The professor and chief, of oncology and hematology at University of Nebraska Medical Center discussed research with CAR T therapy in lymphoma.
CAR T Therapy in Non-Hodgkin Lymphoma: Kelly Garvin, BSN, RN
The lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.
Targeting LHON and Retinitis Pigmentosa With Gene Therapy
Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed the company’s work in ophthalmic diseases.
Allogeneic vs Autologous CAR T-Cell Therapies
The chief executive and chief medical officer of Celyad Oncology discussed the advantages of allogeneic CAR T therapies over autologous ones.
Understanding the Genetics of Age-Related Macular Degeneration: Gregory S. Hageman, PhD
The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed the research his team has been conducting in AMD.
Weighing Benefits and Risks of Cell Therapy in Multiple Myeloma: Suzanne Lentzsch, MD
The professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, New York-Presbyterian Hospital, discussed utility of cellular therapies in multiple myeloma.
Selecting CAR T-Cell Therapies for R/R DLBCL
Experts discuss the use and selection of CAR T therapies in relapsed/refractory diffuse large B-cell lymphoma.
Activating SCN1A to Treat Dravet Syndrome
Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the company’s gene therapy pipeline, including their lead program ETX101.
Selecting CAR T-Cell Therapies for Mantle Cell Lymphoma: Jae Park, MD
The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed factors to consider in selecting CAR T-cell therapies.
Patient Considerations in R/R Mantle Cell Lymphoma Treatment: Anita Kumar, MD
The Regional Care Network Medical Site Director at Memorial Sloan Kettering Cancer Center Basking Ridge discussed patient factors to consider when selecting treatment in R/R MCL.
Brexucabtagne Autoleucel's Efficacy in ALL: Bijal Shah, MD, MS
The associate member in the Department of Malignant Hematology at Moffitt Cancer Center discussed results of the ZUMA-3 trial.
Novel Treatments for Multiple Myeloma: C. Ola Landgren, MD, PhD
The inaugural leader of the Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, University of Miami discussed exciting novel therapeutic approaches in multiple myeloma.
Improving AAV Production With HeLa Platform
Sam Wadsworth, PhD, chief scientific officer of Ultragenyx Pharmaceuticals, discussed the company’s platform for efficiently producing AAV vectors.
Targeting Relapsing/Refractory Multiple Myeloma With Cell Therapy
The president and chief operating officer of Agenus discussed the cell therapies the company is developing for the treatment of multiple myeloma.
Investigating JSP191 for More Tolerable Gene and Cell Therapy Conditioning
The executive vice president of research and development at Jasper Therapeutics discussed positive data from trials of JSP191 in MDS and AML.
Advantages of CG0070 Over Standard Care for Non-Muscle Invasive Bladder Cancer
The chief executive officer of CG Oncology discussed the role of CG0070 in patients who are unresponsive and responsive to Bacillus Calmette-Guerin immunotherapy.
CAR T-Cell Therapy for Mantle Cell Lymphoma: Tycel Jovelle Phillips, MD
The clinical associate professor from the Rogel Cancer Center at Michigan Medicine discussed the future of CAR T-cell therapy in mantle cell lymphoma patients.
Targeting Leptomeningeal Brain Tumors With CAR T Therapy
Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio, discussed upcoming research on MB-101 cell therapy.
The Need for New Therapies in DLBC Lymphoma: Gilles Salles, MD
The lymphoma service chief at Memorial Sloan Kettering Cancer Center discussed the need for new therapies to treat diffuse large B-cell lymphoma.
CAR T and Other Approaches for Patients with R/R DLBC Lymphoma
Loretta Nastoupil, MD, and John Burke, MD, discussed treating relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Improving Gene and Cell Therapy Conditioning Regimens With JSP191
The executive vice president of research and development at Jasper Therapeutics discussed how JSP191 is designed to be better-tolerated than current conditioning regimens.
Novel Treatments for Hematologic Malignancies: Julie Vose, MD
The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed novel treatment options for patients with hematologic malignancies.
CG0070: A Genetically Modified Immunotherapy for Non-Muscle Invasive Bladder Cancer
The first patient in CG Oncology's phase 2 study of CG0070 was dosed in December 2020.
